Biotech Values

[DewDiligence]

ACRS/INCY—If [ACRS] have a novel compound with its own IP, why do they need use patents of baricitinib / juxolitinib? Is it in an attempt to block the latter two from being used in that indication?

Or an attempt to collect a royalty. In a similar vein, ABBV obtained a patent on the use of GILD's Sovaldi for treating HCV before GILD itself did, sparking a lawsuit that has yet to be concluded (#msg-104483323).